Hennion & Walsh Asset Management Inc. Decreases Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Hennion & Walsh Asset Management Inc. decreased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 114,534 shares of the company’s stock after selling 4,449 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Amylyx Pharmaceuticals were worth $371,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its stake in shares of Amylyx Pharmaceuticals by 52,575.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock worth $43,000 after purchasing an additional 15,247 shares during the last quarter. Algert Global LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $47,000. CWM LLC increased its stake in shares of Amylyx Pharmaceuticals by 104.2% during the 2nd quarter. CWM LLC now owns 28,643 shares of the company’s stock worth $54,000 after purchasing an additional 14,613 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Amylyx Pharmaceuticals by 113.6% during the 2nd quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock worth $106,000 after purchasing an additional 29,697 shares during the last quarter. Finally, Hsbc Holdings PLC increased its stake in shares of Amylyx Pharmaceuticals by 57.9% during the 2nd quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after purchasing an additional 27,954 shares during the last quarter. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $5.07 on Wednesday. The firm has a fifty day moving average price of $3.17 and a two-hundred day moving average price of $2.34. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $19.95. The company has a market cap of $344.79 million, a price-to-earnings ratio of -4.74 and a beta of -0.55.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The firm had revenue of ($1.02) million during the quarter, compared to the consensus estimate of $18.83 million. During the same period in the previous year, the business earned $0.31 earnings per share. Equities research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AMLX has been the subject of several research analyst reports. Leerink Partners set a $4.00 price target on shares of Amylyx Pharmaceuticals and gave the stock a “market perform” rating in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a report on Friday, October 18th. The Goldman Sachs Group raised their price objective on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Friday, July 12th. Finally, Bank of America raised shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $4.20 to $10.00 in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Hold” and an average target price of $14.57.

Insider Buying and Selling at Amylyx Pharmaceuticals

In related news, Director George M. Milne, Jr. acquired 100,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were purchased at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the transaction, the director now owns 858,571 shares in the company, valued at $1,888,856.20. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO James M. Frates acquired 40,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $2.53 per share, for a total transaction of $101,200.00. Following the transaction, the chief financial officer now owns 233,464 shares in the company, valued at $590,663.92. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director George M. Milne, Jr. acquired 100,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were bought at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the transaction, the director now owns 858,571 shares in the company, valued at approximately $1,888,856.20. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 11.70% of the company’s stock.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.